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Clonal hematopoiesis increases with age, where a single mutant hematopoietic stem or progenitor cell 
contributes to a significant, measurable clonal proportion of mature blood lineages.1-5 Evolution of mutant 
clonal hematopoiesis with age predisposes the elderly to myelodysplastic syndromes (MDS),  acute 
myeloid leukemia (AML), and other aging-associated diseases, suggesting that mutations identified in 
hematopoietic stem cells contribute to disease development.1-5 However, the mechanisms by which age-
induced stem cell mutations cause clonal expansion of hematopoietic stem cell are largely unknown.   
 Recently, acquired somatic mutations in TP53 gene were identified in the blood of aged healthy 
individuals and the frequency of TP53 mutations increases with age.3-5 TP53 mutations rank top five 
among mutations identified in aged healthy individuals. 3-5 The TP53 gene, which encodes the tumor 
suppressor p53, is the most frequent target for mutation in human cancer, including hematological 
malignancies.6 TP53 mutations are present in 10% of MDS cases and 20 to 30% in secondary MDS arising 
after exposure to radiation or alkylating agents. 1, 7 The frequency of TP53 mutations in AML is 
approximately 10%. However, in AML with complex karyotype, the frequency of p53 mutations and/or 
deletions is almost 70%. 8 Further, TP53 mutations are associated with poor prognosis and decreased 
survival in MDS and AML. 7-9 However, the role of TP53 mutations in clonal hematopoiesis and the 
pathogenesis of hematological malignancies is largely unknown.  
 To date, no studies have investigated the in vivo effect of TP53 mutations expressed from the 
endogenous locus in hematopoietic cells, which might allow delineation of how these mutations contribute 
to the pathogenesis of hematological malignancies. 10-13 The vast majority of missense TP53 mutations 
are mapped to the DNA-binding domain (DBD) of p53 protein, and usually abrogate its sequence-specific 
DNA-binding activity.6 Previous studies show that codon 248 of the p53 protein is most frequently 
mutated in MDS and AML.7-8 p53R248W mutant has also been identified in aged healthy individuals.3-5 To 
better understand the role of mutant p53 in hematopoiesis when expressed physiologically from its 
endogenous promoter, we utilized the humanized p53R248W knock-in mice, expressing human p53 mutant 
protein from the endogenous murine Trp53 promoter.14 Given that most TP53 mutations in clonal 
hematopoiesis and hematological malignancies are monoallelic missense mutations,3-9  we examined HSC 
 
 
function in the heterozygous p53R248W/+ mice to recapitulate clinical conditions. We first analyzed the 
peripheral blood and bone marrow of p53+/+ and p53R248W/+ mice (8 to 12 week-old). Peripheral blood cell 
counts and bone marrow cellularity were comparable among these mice (Figures S1a, S1b, S1c, S1d, S1e, 
and S1f). In p53 knockout mice, there is a dramatic increase of LT-HSCs;11 however, we found that p53+/+ 
and p53R248W/+ mice have a similar number of LT-HSCs (Figures 1a and S1g). In addition, expression of 
p53R248W did not affect the frequency of myeloid progenitors (Figures 1a, 1b, and S1g). To determine the 
role of p53R248W in hematopoiesis in vivo, we performed competitive bone marrow transplantation assays 
as shown in Figure S1h. We transplanted 5 x 105 donor bone marrow cells (p53+/+ or  p53R248W/+, CD45.2+) 
into lethally irradiated (9.5 Gy) recipient mice (CD45.1+CD45.2+) along with 5 x 105 competitor marrow 
cells (CD45.1+). At 16 weeks post transplantation, the repopulating ability of p53R248W/+ cells was 
significantly higher than that of the wild type cells (Figure 1c). We also observed increased frequency of 
donor-derived hematopoietic stem and progenitor cells in the bone marrow of recipient mice repopulated 
with p53R248W/+ cells (Figures 1d, 1e, and S1i). p53R248W did not affect myeloid and lymphoid 
differentiation in the peripheral blood and the bone marrow of the primary recipient mice (Figures 1f and 
1g). We then transplanted 3 x 106 bone marrow cells isolated from the primary recipient mice into lethally 
irradiated secondary recipients. Sixteen weeks after transplantation, p53R248W/+ cells continued to show 
increased repopulating ability (Figure 1h). p53R248W did not affect myeloid and lymphoid differentiation 
in the peripheral blood of secondary recipients  (Figure 1i). These findings suggest that expression of 
mutant p53 in normal HSCs does not cause leukemic transformation, but rather generates a premalignant 
state.15 
 HSCs in aged mice have decreased per-cell repopulating activity, self-renewal and homing abilities, 
myeloid skewing of differentiation, and increased apoptosis with stress.1,16 To determine the role of 
mutant p53 in hematopoiesis during aging, we maintained the secondary transplantation recipient mice 
shown in Figure 1h for more than 12 months. We observed enhanced repopulating potential of p53R248W/+ 
bone marrow cells compared to p53+/+ cells 48 weeks after transplantation (Figure 1j). We found 
 
 
decreased frequency of donor-derived myeloid cells and increased frequency of lymphoid cells in the PB 
of the recipients repopulated with p53R248W/+ cells (Figure 1k).  
Tumor suppressor regulates HSC quiescence and response to genotoxic stress.11  Given that p53-
/- mice are resistant to 5-FU treatment,10 we hypothesized that p53R248W/+ mice may be resistant to 
chemotherapy treatment.  We treated p53+/+ and p53R248W/+ mice with 5-FU weekly and then monitored 
their survival. While most wild-type mice were died 4 weeks following 5-FU treatment, all p53R248W/+ 
mice were still alive (Figure 2a). To measure the kinetics of hematopoietic recovery, we administered a 
single dose of 5-FU (200mg/kg) and serially followed peripheral blood cell counts. 5-FU-treated 
p53R248W/+ mice had less severe leukopenia than p53+/+ mice, with more rapid recovery (Figures 2b, S2a, 
S2b, S2c, and S2d). We treated p53+/+ and p53R248W/+ mice with one dose of 5-FU (200mg/kg) and then 
examined bone marrow cellularity, HSC frequency, and apoptosis one week later. We found that 
p53R248W/+ mice exhibited higher bone marrow cellularity compared to p53+/+ mice following 5-FU 
treatment (Figure S2e). There were more hematopoietic stem and progenitor cells in the bone marrow of 
5-FU treated p53R248W/+ mice compared to that of the p53+/+ mice (Figures 2c, S2f, and S2g). Moreover, 
p53R248W/+ hematopoietic stem and progenitor cells were less apoptotic compared to p53+/+ HSPCs 
following 5-FU treatment (Figures 2d and S2h).  
To determine the impact of 5-FU treatment on p53R248W/+ hematopoietic cells in vivo, we 
performed serial competitive transplantation assays using live bone marrow cells isolated from p53+/+ 
and p53R248W/+ mice treated with one dose of 5-FU (Figure S2i). We found that 5-FU treated p53R248W/+ 
bone marrow cells showed enhanced repopulation potential compared to 5-FU treated p53+/+ cells at 16 
weeks following primary transplantation (Figure 2e). Multi-lineage differentiation of hematopoietic 
stem and progenitor cells in the peripheral blood was comparable in p53+/+ and p53R248W/+ mice (Figure 
2f). We then transplanted 3 x 106 BM cells isolated from primary recipient mice into lethally irradiated 
secondary recipient mice. p53R248W/+ bone marrow cells continued to show enhanced engraftment 
compared to p53+/+ cells at 16 weeks following secondary transplantation (Figure 2g). Mutant p53 did 
not affect differentiation in the peripheral blood and the bone marrow of secondary recipient mice 
 
 
(Figures 2h and S2j).  The frequency of donor-derived hematopoietic stem and progenitor cells was 
significantly increased in the BM of secondary recipient mice repopulated with mutant BM cells (Figure 
2i). To determine the impact of mutant p53 on DNA damage response, we treated wild type and mutant 
p53 mice with DMSO or 5-FU and then examined the expression of p53 target gene p21 in HSPCs. 
While the mRNA levels of p21 were significantly increased in wild-type cells following 5-FU treatment, 
the expression of p21 in mutant cells was not induced by 5-FU treatment (Figure 2j).  
To determine whether functional TP53 mutations promote clonal expansion of HSCs following 
chemotherapy treatment, we generated mixed bone marrow chimaeras containing both p53+/+ and 
p53R248W/+ cells (the ratio of p53+/+ to p53R248W/+ cells is 10:1). 8 weeks following transplantation, 
recipient mice were treated with DMSO or chemotherapy drug N-ethyl-N-nitrosourea (ENU), 
respectively (Figure S3a). While DMSO treatment did not affect the repopulating ability of p53R248W/+ 
HSCs, p53R248W/+ HSCs outcompeted p53+/+ cells and become clonal dominance upon ENU treatment 
(Figure 2k).  ENU treatment did not affect the differentiation of p53+/+ and p53R248W/+ HSCs in the 
peripheral blood of recipient mice (Figure S3b). The frequency of mutant LSKs was significantly 
increased in the BM of recipient mice at 16 weeks following ENU treatment (Figures 2i and S3c).  We 
sacrificed the recipient mice at 16 weeks following DMSO or ENU treatment and then performed 
pathological analysis to detect tumor formation. While there were no tumors in recipient mice treated 
with DMSO, 4 out of 7 recipient mice treated with ENU developed lymphoma and thymoma (data not 
shown).  
Given p53 null hematopoietic stem and progenitor cells are less sensitive to irradiation, 11-13 we 
examined the impact of mutant p53 on HSC function flowing irradiation. We found that HSCs 
expressing mutant p53 show decreased apoptosis and increased repopulating potential compared to wild 
type HSCs following irradiation. Furthermore, p53R248W/+ HSCs show competitive advantage over 
p53+/+ cells and underwent clonal expansion following total body irradiation (SC and YL, unpublished 
data).  
 
 
Thus, we have identified a critical role for mutant p53 in regulating the response of HSCs to 
genotoxic stresses. Further, we discovered that chemotherapy and radiotherapy cause the expansion of 
HSCs expressing mutant p53. While mutant p53 proteins accumulate in cancer cells, the levels of 
mutant p53 proteins in normal cells are very low. 14, 17 Genotoxic stresses stabilize mutant p53 in 
hematopoietic cells.14, 17-18 Given that the p53R248W mutant has both dominant-negative (DN) and gain-
of-function (GOF) roles in human cancer,6, 14 stabilized mutant p53 may inhibit the wild type p53 
function or gain new oncogenic functions through protein-protein interactions to promote leukemic 
transformation. In addition, the expansion of mutant HSCs following genotoxic stresses may increase 
the possibility of acquiring additional genetic and/or epigenetic changes that facilitate leukemic 
transformation.  
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FIGURE LEGENDS 
 
Figure 1. Mutant p53 enhances the repopulating potential of bone marrow cells. (a) The frequency of LT-
HSCs, ST-HSCs, MPPs, and LSKs in the BM of young p53+/+ and p53R248W/+ mice. n=10 mice per 
genotype. (b) The frequency of CMPs, MEPs, GMPs, and Lin-Kit+ cells in the bone marrow of young 
p53+/+ and p53R248W/+ mice. n=10 mice per genotype. (c) Percentage of donor-derived (CD45.2+) cells in 
the peripheral blood of primary recipient mice post-transplantation, measured at 4-week intervals. 
**p<0.01, ***p<0.001, n=7 mice per group. (d) The frequency of donor-derived LT-HSCs, ST-HSCs, 
MPPs, and LSKs in the bone marrow of primary recipient mice 16 weeks following transplantation. 
*p<0.05, ***p<0.001, n = 7 mice per group.  (e) The frequency of donor-derived MEPs, CMPs, GMPs, 
and myeloid progenitors (Lin-Kit+) in the bone marrow of primary recipient mice 16 weeks following 
transplantation. *p<0.05, **p<0.01, n = 7 mice per group.  (f) The percentage of donor-derived myeloid 
cells (Gr1+), B cells (B220+), and T cells (CD3e+) in the peripheral blood of primary recipient mice 16 
weeks following transplantation. n=7 mice per group. (g) The percentage of donor-derived myeloid cells, 
B cells, and T cells in the bone marrow of primary recipient mice 16 weeks following transplantation. n 
= 7 mice per group. (h) The percentage of donor-derived cells in the peripheral blood of secondary 
recipient mice. ***p<0.001, n=7 mice per group. (i) The percentage of donor-derived myeloid cells, B 
cells, and T cells in the peripheral blood of secondary recipient mice 16 weeks following transplantation. 
n=7 mice per group. (j) The percentage of donor-derived cells in the peripheral blood of secondary 
recipients 48 weeks after transplantation. ***p<0.001, n=7 mice per group. (k) The percentage of donor-
derived myeloid cells, B cells, and T cells in the peripheral blood of secondary recipient mice 48 weeks 
after transplantation. *p<0.05, **p<0.01, n=7 mice per group. 
Figure 2. Chemotherapy treatment promotes clonal expansion of HSCs expressing mutant p53. (a) 
Kaplan-Meier survival curve of p53+/+ and p53R248W/+ mice following weekly 5-FU treatment. 5-FU was 
administered intraperitoneally weekly (the initial dose was 125 mg/kg, with subsequent doses of 90 
mg/kg) for 3 weeks and the survival rates of 5-FU treated mice were measured. Results were analyzed 
 
 
with a log-rank nonparametric test and expressed as Kaplan-Meier survival curves (***p<0.001, n = 10 
mice per group). (b) Hematopoietic recovery of p53+/+ and p53R248W/+ mice following a single dose of 5-
FU treatment (200 mg/kg intraperitoneally). WBC counts are shown at each point after 5-FU 
administration as a percentage of the initial values for each group of mice. Mean ± SEM values are shown 
(*p<0.05, **p<0.01, ***p<0.001, n = 5 mice per group for each time point).  (c) Absolute number of 
HSCs (Lin-Sca1+CD48-CD150+ cells) in the bone marrow of p53+/+ and p53R248W/+ mice seven days after 
a single dose of 5-FU treatment (200 mg/kg intraperitoneally). Mean ± SEM values are shown (**p<0.01, 
n = 5 mice per group). (d) The percentage of early apoptotic (AnnexinV+DAPI-) HSCs (Lin-Sca1+CD48-
CD150+ cells) in the bone marrow of p53+/+ and p53R248W/+ mice seven days after a single dose of 5-FU 
treatment (200 mg/kg intraperitoneally). Mean ± SEM values are shown (**p<0.01, n = 5 mice per group). 
(e) The percentage of donor-derived cells in the peripheral blood of primary recipient mice reconstituted 
with bone marrow cells from 5-FU treated p53+/+ and p53R248W/+ mice. Mean ± SEM values are shown 
(***p<0.001, n = 7-8 mice per group). (f) The percentage of donor-derived myeloid cells (Gr1+), B cells 
(B220+), and T cells (CD3e+) in the peripheral blood of secondary recipient mice 16-weeks after 
transplantation. Mean ± SEM values are shown (n.s, p>0.05, n = 7-8 mice per group). (g) The percentage 
of donor-derived cells in the peripheral blood of secondary recipient mice. Mean ± SEM values are shown 
(***p<0.001, n = 7-8 mice per group). (h) The percentage of donor-derived myeloid cells, B cells, and T 
cells in the peripheral blood of secondary recipient mice 16-weeks after transplantation. Mean ± SEM 
values are shown (n.s, p>0.05, n = 7-8 mice per group). (i) The chimerism of donor-derived LT-HSCs, 
ST-HSCs, and MPPs in the bone marrow of secondary recipient mice at 16 weeks following 
transplantation. Mean ± SEM values are shown (*p<0.05, **p<0.01, ***p<0.001, n = 7-8 mice per group). 
(j) The mRNA levels of p53 target gene p21 in hematopoietic stem and progenitor cells isolated from 
p53+/+ and p53R248W/+ mice treated with DMSO or 5-FU were determined by quantitative real-time PCR 
analysis. **p<0.01, n = 3. (K) Mutant p53 promotes clonal expansion of HSCs following chemotherapy 
treatment. The percentage of p53R248W/+ cells (CD45.2+) in the peripheral blood of recipient mice 
following ENU or DMSO treatment was determined by flow cytometry analysis at monthly intervals. 
 
 
Mean ± SEM values are shown (***p<0.001, n = 7 mice per group). (l) The frequency of p53R248W/+ LSK 
cells (CD45.2+) in the bone marrow of recipient mice at 16 weeks following ENU or DMSO treatment. 
Mean ± SEM values are shown (*p<0.05, n = 7 mice per group).  
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Genotoxic stresses promote clonal expansion of hematopoietic stem cells expressing mutant p53 
 
 
Supplemental Methods 
Mice  
The humanized p53 knock-in mice (HUPKI, p53+/+) and p53R248W/+ mice have been backcrossed to the 
C57BL6 background for at least 8 generations (Song et al., 2007). All p53+/+ and p53R248W/+ mice used in 
these studies are 8 to 12 weeks old and are tumor free. Wild type C57BL/6 (CD45.2+), B6.SJL (CD45.1+) 
and F1 mice (CD45.2+ CD45.1+) mice were obtained from an on-site core breeding colony. All mice were 
maintained in the Indiana University Animal Facility according to IACUC-approved protocols.  
Flow cytometry  
Flow cytometry analysis of hematopoietic stem and progenitor cells was performed as described 
previously (Liu et al., 2009). Murine hematopoietic stem and progenitor cells were identified and 
evaluated by flow cytometry using a single cell suspension of bone marrow mononuclear cells (BMMCs). 
Hematopoietic stem and progenitors are purified based upon the expression of surface markers. Bone 
marrow (BM) cells were obtained from femurs by flushing cells out of the bone using a syringe and 
phosphate-buffered saline (PBS) with 2mM EDTA. Red blood cells (RBCs) were lysed by RBC lysis 
buffer (eBioscience) prior to staining. Experiments were performed on FACS LSR IV cytometers (BD 
Biosciences) and analyzed by using the FlowJo Version 9.3.3 software (TreeStar). 
Transplantation  
For the competitive repopulation assays, we injected 5 x 105 BM cells from p53+/+ and p53R248W/+ mice 
(CD45.2+) plus 5 x 105 competitor BM cells (CD45.1+) into 9.5Gy lethally irradiated F1 mice 
(CD45.1+CD45.2+). Peripheral blood was obtained by tail vein bleeding every 4-week after 
transplantation, RBC lysed, and the PB mononuclear cells stained with anti-CD45.2 FITC and anti-
 
 
CD45.1 PE, and analyzed by flow cytometry. 16 weeks following transplantation, bone marrow cells from 
recipient mice were analyzed to evaluate donor chimerism in bone marrows. For secondary 
transplantation, 3X106 BM cells from mice reconstituted with p53+/+ or p53R248W/+ BM cells were injected 
into 9.5Gy lethally irradiated F1 mice (CD45.1+CD45.2+).  
 
We treated p53+/+ and p53R248W/+ mice (CD45.2+) with a single dose of 5-FU (200 mg/kg 
intraperitoneally). 7 days later, we injected 5 x 105 live BM cells from 5-FU treated p53+/+ and p53R248W/+ 
mice (CD45.2+) plus 5 x 105 competitor BM cells (CD45.1+) into lethally irradiated (9.5Gy) F1 mice 
(CD45.1+CD45.2+). Peripheral blood was obtained by tail vein bleeding every 4-week after 
transplantation, RBC lysed, and the PB mononuclear cells stained with anti-CD45.2 FITC and anti-
CD45.1 PE, and analyzed by flow cytometry. For secondary transplantation, 3x106 BM cells from primary 
recipient mice reconstituted with p53+/+ or p53R248W/+ BM cells were injected into lethally irradiated 
(9.5Gy ) F1 mice (CD45.1+CD45.2+).  
Apoptosis assays 
Bone marrows were stained with cell surface markers as described above. After staining, cells were 
washed with 0.2% BSA in PBS, and suspended in 1 x Annexin V binding buffer (eBiosciences) and 
then incubated with FITC-conjugated-AnnexinV (eBiosciences) and 4′,6-diamidino-2-phenylindole 
(DAPI) (Sigma) at room temperature for 30 mines. Cells were acquired using LSR IV flow cytometer. 
Data analysis was performed using FlowJo software. Early apoptotic cells were defined as Annexin V+ 
DAPI- cells. 
Statistical Analysis 
Statistical analysis was performed with GraphPad Prism 6 software (GraphPad software, Inc). All data 
are presented as mean ± standard error of the mean (SEM). The sample size for each experiment are 
included in the figure legends. Statistical analyses were performed using unpaired, two-tailed Student’s t 
 
 
test where applicable for comparison between two groups, and a One-way ANOVA test or Two-way 
ANOVA was used for experiments involving more than two groups. Statistical significance was defined 
as *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant. 
 
Supplementary Figure Legends 
 
Figure S1. (a) White blood cell, (b) Neutrophil, (c) lymphocyte, (d) Red blood cell, and (e) Platelet counts 
in the peripheral blood of p53+/+ and p53R248W/+ mice (8 to 12 weeks old). n=5 mice per group. (f) Bone 
marrow cell numbers from p53+/+ and p53R248W/+ mice. n=10 mice per group. (g) The frequency of LT-
HSCs (CD48-CD150+LSKs), ST-HSCs (CD48-CD150-LSKs), MPPs (CD48+CD150-LSKs), CMPs 
(Lin−Sca1−Kit+FcγRII/IIIlowCD34high), GMPs (Lin−Sca1−Kit+FcγRII/IIIhighCD34high) and MEPs 
(Lin−Sca1−Kit+FcγRII/IIIlowCD34low) in the bone marrow of p53+/+ and p53R248W/+ mice was determined 
by flow cytometry analysis of cell surface markers. Representative flow cytometry plots of hematopoietic 
stem and progenitor cells are shown. (h) Experimental schema of competitive bone marrow 
transplantation assays. (i) The percentage of donor-derived cells (CD45.2+) in the bone marrow of primary 
recipient mice 16 weeks following transplantation was determined by flow cytometry analysis. n = 7 mice 
per group, *p<0.05. 
  
Figure S2. (a) Lymphocyte, (b) Neutrophil, (c) Red blood cell, and (d) Platelet counts in the peripheral 
blood of p53+/+ and p53R248W/+ mice following a single dose of 5-FU treatment (200 mg/kg 
intraperitoneally). Cell counts are shown at each point after 5-FU administration as a percentage of the 
initial values for each group of mice. Mean ± SEM values are shown (*p<0.05, **p<0.01, ***p<0.001, n 
= 5 mice per group for each time point).  (e) Bone marrow cell counts of p53+/+ and p53R248W/+ mice seven 
days after a single dose of 5-FU treatment (200 mg/kg intraperitoneally). Mean ± SEM values are shown 
(***p<0.001, n = 5 mice per group). (f) The frequency of HSCs (Lin-Sca1+CD48-CD150+ cells) in the 
 
 
bone marrow of p53+/+ and p53R248W/+ mice seven days after a single dose of 5-FU treatment (200 mg/kg 
intraperitoneally). Mean ± SEM values are shown (*p<0.05, n = 5 mice per group). (g) The frequency of 
MPPs (Lin-Sca1+CD48+CD150- cells) in the bone marrow of p53+/+ and p53R248W/+ mice seven days after 
a single dose of 5-FU treatment (200 mg/kg intraperitoneally). Mean ± SEM values are shown (*p<0.05, 
n = 5 mice per group). (h) The percentage of early apoptotic (AnnexinV+DAPI-) MPPs (Lin-
Sca1+CD48+CD150- cells) in the bone marrow of p53+/+ and p53R248W/+ mice seven days after a single 
dose of 5-FU treatment (200 mg/kg intraperitoneally). Mean ± SEM values are shown (**p<0.01, n = 5 
mice per group). (i) Experimental schema of competitive bone marrow transplantation assays using live 
bone marrow cells isolated from p53+/+ and p53R248W/+ mice treated with 5-FU. (j) The percentage of 
donor-derived myeloid cells, B cells, and T cells in the BM of secondary recipient mice 16-weeks after 
transplantation. Mean ± SEM values are shown (n.s, p>0.05, n = 7-8 mice per group). 
Figure S3. (a) Bone marrow chimaeras were generated by transplanting a 10:1 ratio of p53+/+ cells (CD45. 
1+) to p53R248W/+ cells (CD45.2+) into irradiated recipient mice (CD45.1+CD45.2+). After hematopoietic 
reconstitution (8-weeks after transplantation), mice were treated with DMSO or ENU (100mg/kg two 
doses, 9 days apart). (b) The percentage of p53R248W/+ (CD45.2+) myeloid cells (Gr1+), B cells (B220+) 
and T cells (CD3e+) in the peripheral blood of recipient mice 16-weeks following ENU or DMSO 
treatment. Mean ± SEM values are shown (n.s, p>0.05, n = 7 mice per group). (c) The frequency of 
p53R248W/+ cells (CD45.2+) in the bone marrow of recipient mice 16-weeks following ENU or DMSO 
treatment. Mean ± SEM values are shown (*p<0.05, n = 7 mice per group).  
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